The estimated Net Worth of Elizabeth E Reed is at least $2.09 Milion dollars as of 16 November 2020. Ms. Reed owns over 2,500 units of Retrophin stock worth over $1,780 and over the last 8 years she sold RTRX stock worth over $510,080. In addition, she makes $1,582,450 as Senior Vice President i General Counsel and Corporate Secretary at Retrophin.
Sign up
Ms. Reed RTRX stock SEC Form 4 insiders trading
Elizabeth has made over 12 trades of the Retrophin stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 2,500 units of RTRX stock worth $59,950 on 16 November 2020.
The largest trade she's ever made was selling 5,000 units of Retrophin stock on 14 November 2018 worth over $120,150. On average, Elizabeth trades about 1,307 units every 55 days since 2017. As of 16 November 2020 she still owns at least 25,431 units of Retrophin stock.
You can see the complete history of Ms. Reed stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Elizabeth Reed biography
Elizabeth E. Reed is the Senior Vice President, General Counsel and Corporate Secretary of the Company. Ms. Reed brings a diverse knowledge base to Retrophin that has been cultivated over a 20-year career at emerging biopharmaceutical companies and leading law firms. Ms. Reed most recently served as general counsel and secretary of Celladon Corporation. Previously, Ms. Reed led the legal function at Anadys Pharmaceuticals, Inc., serving as general counsel and corporate secretary. Prior to these roles, Ms. Reed amassed foundational experience at the law firms Cooley Godward LLP and Brobeck, Phleger & Harrison LLP. Ms. Reed received her J.D. from Harvard Law School and her B.S. in Business Administration from the University of California at Berkeley.
What is the salary of Elizabeth Reed?
As the Senior Vice President i General Counsel and Corporate Secretary of Retrophin, the total compensation of Elizabeth Reed at Retrophin is $1,582,450. There are 1 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of $9,679,320.
How old is Elizabeth Reed?
Elizabeth Reed is 49, she's been the Senior Vice President i General Counsel and Corporate Secretary of Retrophin since 2017. There are 12 older and 1 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.
What's Elizabeth Reed's mailing address?
Elizabeth's mailing address filed with the SEC is C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO, CA, 92130.
Insiders trading at Retrophin
Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer oraz Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.
What does Retrophin do?
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
What does Retrophin's logo look like?
Complete history of Ms. Reed stock trades at Retrophin
Retrophin executives and stock owners
Retrophin executives and other stock owners filed with the SEC include:
-
Eric Dube,
President, Chief Executive Officer, Director -
Elizabeth Reed,
Senior Vice President, General Counsel and Corporate Secretary -
Noah Rosenberg,
Chief Medical Officer -
Peter Heerma,
Chief Commercial Officer -
William Rote,
Senior Vice President and Head of Research and Development -
Laura Clague,
Chief Financial Officer, Senior Vice President -
Stephen Aselage,
Director -
Sandra Poole,
Independent Director -
Gary Lyons,
Independent Chairman of the Board -
Timothy Coughlin,
Independent Director -
Jeffrey Meckler,
Independent Director -
John Orwin,
Independent Director -
Roy Baynes,
Independent Director -
Ron Squarer,
Independent Director -
Suzanne Bruhn,
Independent Director -
Neil F. Mc Farlane,
Chief Operating Officer -
Jensen Margaret E Valeur,
General Counsel -
John W Kozarich,
Director -
Alvin Shih,
EVP of Research & Development -
Cornelius E Golding,
Director -
Steve Aselage,
Director -
Martin Shkreli,
Chief Executive Officer -
Steven Gary Richardson,
Director -
Horacio Plotkin,
Chief Medical Officer -
Jeffrey Paley,
Director -
Marc L Panoff,
Chief Financial Officer